Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia

Syk inhibitors in clinical development for hematological malignancies

(2017) Delong Liu et al.   Journal of Hematology & Oncology

Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy

(2017) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

(2017) Ellen L. Weisberg et al.   Oncotarget

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms

(2017) Annette K. Brenner et al.   Frontiers in Immunology

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

(2016) P. M. Barr et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

(2016) Srini Ramanathan et al.   CLINICAL DRUG INVESTIGATION

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

(2016) Ian W. Flinn et al.   EUROPEAN JOURNAL OF CANCER

Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia

(2016) Isabelle Laverdière et al.   EXPERIMENTAL HEMATOLOGY

Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells

(2016) Tor Henrik Tvedt et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1

(2016) A Abdelbaset-Ismail et al.   LEUKEMIA

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia

(2016) B M Richine et al.   LEUKEMIA

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells

(2016) Annette Brenner et al.   MOLECULES

Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity

(2016) Hai Yi et al.   Oncotarget

Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells

(2016) Chirag A. Shah et al.   Oncotarget

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators

(2016) Annette K. Brenner et al.   Frontiers in Immunology

VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia

(2015) Mi Hyun Bae et al.   ANNALS OF HEMATOLOGY

Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer

(2015) Mariya O. Krisenko et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

B Cells in Chronic Graft-versus-Host Disease

(2015) Stefanie Sarantopoulos et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease

(2015) R. Flynn et al.   BLOOD

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

(2015) J. Sharman et al.   BLOOD

Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia

(2015) Xin Long et al.   BRITISH JOURNAL OF HAEMATOLOGY

Microenvironmental Remodeling as a Parameter and Prognostic Factor of Heterogeneous Leukemogenesis in Acute Myelogenous Leukemia

(2015) Jin-A Kim et al.   CANCER RESEARCH

CCN1 acutely increases nitric oxide production via integrin α v β 3 –Akt–S6K–phosphorylation of endothelial nitric oxide synthase at the serine 1177 signaling axis

(2015) Soojin Hwang et al.   FREE RADICAL BIOLOGY AND MEDICINE

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells

(2015) Sawa Ito et al.   Stem Cell Research

Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia

(2015) Katalin Boros et al.   Oncotarget

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients

(2015) H. Reikvam et al.   CELL PROLIFERATION

SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia

(2014) Alexandre Puissant et al.   CANCER CELL

Inflammasome: Putting the Pieces Together

(2014) Jürgen Ruland   CELL

Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease

(2014) Doanh Le Huu et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

(2014) Kevin S. Currie et al.   JOURNAL OF MEDICINAL CHEMISTRY

The integrin adhesome: from genes and proteins to human disease

(2014) Sabina E. Winograd-Katz et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Getting Syk: spleen tyrosine kinase as a therapeutic target

(2014) Robert L. Geahlen   TRENDS IN PHARMACOLOGICAL SCIENCES

Depletion of STAT5 blocks TEL–SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice

(2014) C Sprissler et al.   Blood Cancer Journal

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

(2014) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells

(2013) Qing-Zhi Long et al.   ANTI-CANCER DRUGS

 2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis

(2013) T. Oellerich et al.   BLOOD

In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

(2013) Peter G. Miller et al.   CANCER CELL

SYK regulates mTOR signaling in AML

(2013) J Carnevale et al.   LEUKEMIA

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

(2013) Hanne Fredly et al.   Clinical Epigenetics

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

(2013) Hanne Fredly et al.   Clinical Epigenetics

The matrix protein CCN1/CYR61 is required for αVβ5-mediated cancer cell migration

(2012) Jana Jandova et al.   CELL BIOCHEMISTRY AND FUNCTION

Decoupling of Tumor-Initiating Activity from Stable Immunophenotype in HoxA9-Meis1-Driven AML

(2012) Kenneth D. Gibbs et al.   Cell Stem Cell

Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels

(2012) F Leonhardt et al.   LEUKEMIA

The osteoclast and its unique cytoskeleton

(2011) Steven L. Teitelbaum   Annals of the New York Academy of Sciences

Integrins, growth factors, and the osteoclast cytoskeleton

(2010) Wei Zou et al.   Annals of the New York Academy of Sciences

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

(2010) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

(2010) M. Buchner et al.   BLOOD

High Expression of the Very Late Antigen-4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group

(2010) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

(2010) Y. Wang et al.   SCIENCE

Src-family and Syk Kinases in Activating and Inhibitory Pathways in Innate Immune Cells: Signaling Cross Talk

(2010) C. A. Lowell   Cold Spring Harbor Perspectives in Biology

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Proteomic and Genetic Approaches Identify Syk as an AML Target

(2009) Cynthia K. Hahn et al.   CANCER CELL

Integrins

(2009) Malgorzata Barczyk et al.   CELL AND TISSUE RESEARCH

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia

(2008) P. S. Becker et al.   BLOOD

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

(2008) M. H. Tomasson et al.   BLOOD

Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3

(2008) Bob Argiropoulos et al.   EXPERIMENTAL HEMATOLOGY

High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease

(2008) A Sergeeva et al.   LEUKEMIA

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid

(2008) Anita Ryningen et al.   LEUKEMIA RESEARCH

Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia

(2008) Emmanuelle Tavernier-Tardy et al.   LEUKEMIA RESEARCH